Zacks Investment Research
15 Jul 2026, 15:46 UTC · 2h ago
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
15 Jul 2026, 15:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AbbVie expects combined sales of Skyrizi and Rinvoq to exceed $31 billion in 2026, reflecting over 20% growth. — Concrete revenue targets and high growth rates for core products directly offset the loss of a major blockbuster drug.
+0.60AbbVie has acquired Apogee Therapeutics to strengthen its business development and investment case. — Strategic acquisitions signal pipeline expansion and a proactive approach to long-term growth.
+0.40Rinvoq is pursuing five new indications, with potential approvals for vitiligo and alopecia areata in 2026/early 2027. — Expanding the addressable market for an existing drug creates incremental revenue upside.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Humira sales continue to decline due to loss of exclusivity and biosimilar erosion. — The loss of a product that once accounted for over 50% of revenue remains a fundamental headwind.
Which stocks this story touches
Strong post-Humira growth strategy, better-than-expected financial performance, and success with Skyrizi and Rinvoq.
Positive sentiment derived from being acquired by AbbVie, strengthening the investment case.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
